首页> 外文期刊>European review for medical and pharmacological sciences. >MicroRNA-205 ameliorates lipid accumulation in non-alcoholic fatty liver disease through targeting NEU1
【24h】

MicroRNA-205 ameliorates lipid accumulation in non-alcoholic fatty liver disease through targeting NEU1

机译:MicroRNA-205通过靶向NEU1改善非酒精性脂肪肝疾病中的脂质蓄积

获取原文
           

摘要

OBJECTIVE: The aim of this study was to explore the role of miR-205 in non-alcoholic fatty liver disease (NAFLD) and explore the underlying mechanism. MATERIALS AND METHODS: High-fat diet (HFD) mice were used as an in vitro model of NAFLD. HepG2 and primary hepatocytes (PH) cells were treated with oleic acid (OA) and considered as in vitro models of NAFLD. qRT-PCR (quantitative real time polymerase chain reaction) and Western blot were respectively employed to investigate mRNA expression and protein expression level. Further analysis was then applied to analyze the underlying mechanisms. Livers were histologically examined using hematoxylin and eosin (H&E) and Oil Red O staining. TargetScan analysis and Luciferase assay were used to identify the target of miR-205. RESULTS: MiR-205 was upregulated and NEU1 was downregulated in both HFD-fed mice and OA-treated HepG2 and PH cells. The overexpression of miR-205 caused the decreased weight of body and liver, downregulation of liver triglyceride, and resulted in the enhancement of glycerol concentration, and finally suppressed lipid accumulation. In addition, the TargetScan analysis and Luciferase assay identified neuraminidase 1 (NEU1) as a novel target of miR-205. In vivo study suggested that the knockdown of NEU1 ameliorated lipid accumulation. Finally, the in vitro investigation showed that the overexpression of miR-205 alleviated lipid accumulation in OA-induced HepG2 and PH cells by targeting NEU1. CONCLUSIONS: Results revealed that miR-205 facilitated lipid accumulation by inhibiting NEU1 in NAFLD, suggesting that miR-205 might be a potential target for the therapeutic strategy for NAFLD.
机译:目的:本研究旨在探讨miR-205在非酒精性脂肪肝疾病(NAFLD)中的作用并探讨其潜在机制。材料与方法:高脂饮食(HFD)小鼠用作NAFLD的体外模型。 HepG2和原代肝细胞(PH)细胞用油酸(OA)处理,并被视为NAFLD的体外模型。分别采用qRT-PCR(定量实时聚合酶链反应)和Western blot研究mRNA表达和蛋白表达水平。然后,进一步的分析被应用于分析潜在的机制。使用苏木精和曙红(H&E)和油红O染色对肝脏进行组织学检查。使用TargetScan分析和荧光素酶测定法鉴定miR-205的靶标。结果:HFD喂养的小鼠和OA处理的HepG2和PH细胞中的MiR-205均被上调,而NEU1被下调。 miR-205的过表达导致人体和肝脏的重量减少,肝脏甘油三酯的下调,并导致甘油浓度的增加,并最终抑制了脂质的积累。此外,TargetScan分析和荧光素酶测定法鉴定神经氨酸酶1(NEU1)为miR-205的新靶标。体内研究表明,NEU1的敲低改善了脂质积聚。最后,体外研究表明,miR-205的过表达通过靶向NEU1减轻了OA诱导的HepG2和PH细胞中的脂质蓄积。结论:结果表明,miR-205通过抑制NAFLD中的NEU1促进脂质蓄积,表明miR-205可能是NAFLD治疗策略的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号